Rxbiologics

Executive Summary

Rxbiologics is a UK-based private biotechnology company founded in 2017, specializing in antibody discovery through its proprietary Galaxy® library platform. The platform enables the generation of fully human antibodies with optimized drug-like properties for therapeutic development. As part of the RxCelerate Group, the company offers end-to-end biologics discovery and development services, positioning itself as a partner for pharmaceutical and biotech firms seeking high-quality antibody candidates. With a focus on preclinical-stage programs, Rxbiologics leverages its library to address targets across multiple disease areas. Despite being in the preclinical stage, Rxbiologics' platform technology and integrated service model provide a foundation for growth. The company is poised to capitalize on the increasing demand for monoclonal antibody therapeutics. Key near-term catalysts include potential licensing or partnership deals, advancement of internal programs, and expansion of its Galaxy library capabilities. With a strong emphasis on drug-like properties, Rxbiologics aims to de-risk antibody development and accelerate timelines for its clients. The company's outlook is promising but contingent on successful validation of its platform through collaborations and pipeline progress.

Upcoming Catalysts (preview)

• Q3 2026Partnership or licensing deal for Galaxy platform50% success
• Q4 2026Advancement of lead antibody program into IND-enabling studies40% success
• Q2 2026Expansion of Galaxy library with new diversity or therapeutic areas60% success